NO944926L - Fremgangsmåter for å inhibere myeloperoksidaseaktivitet - Google Patents

Fremgangsmåter for å inhibere myeloperoksidaseaktivitet

Info

Publication number
NO944926L
NO944926L NO944926A NO944926A NO944926L NO 944926 L NO944926 L NO 944926L NO 944926 A NO944926 A NO 944926A NO 944926 A NO944926 A NO 944926A NO 944926 L NO944926 L NO 944926L
Authority
NO
Norway
Prior art keywords
myeloperoxidase activity
methods
inhibiting myeloperoxidase
inhibiting
bexamethylene
Prior art date
Application number
NO944926A
Other languages
English (en)
Other versions
NO944926D0 (no
Inventor
Andrew Lawrence Glasebrook
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944926D0 publication Critical patent/NO944926D0/no
Publication of NO944926L publication Critical patent/NO944926L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er beskrevet en fremgangsmåte for å Inhibere myeloperoksidaseaktivitet eller en fysiologisk tilstand forbundet med et overskudd derav, som Innbefatter administrering til et menneske som har behov for dette av en effektiv mengde av en forbindelse som har formelen OCHjCHj¿R2 (I) hvori R1 og R3 uavhengig av hverandre er hydrogen. -CH3, 0 9 II D -C-(C1-C6 alkyl), eller -C-Ar, hvor Ar er eventuelt substituert fenyl; R<2 er valgt fra gruppen bestående av pyrrolldln, beksametylenamlno og plperldlno; eller et farmasøytisk akseptabelt salt eller solvat derav.
NO944926A 1993-12-21 1994-12-19 Fremgangsmåter for å inhibere myeloperoksidaseaktivitet NO944926L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,330 US5708009A (en) 1993-12-21 1993-12-21 Methods of inhibiting myeloperoxidase activity

Publications (2)

Publication Number Publication Date
NO944926D0 NO944926D0 (no) 1994-12-19
NO944926L true NO944926L (no) 1995-06-22

Family

ID=22623358

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944926A NO944926L (no) 1993-12-21 1994-12-19 Fremgangsmåter for å inhibere myeloperoksidaseaktivitet

Country Status (16)

Country Link
US (2) US5708009A (no)
EP (1) EP0664125A1 (no)
JP (1) JPH07242546A (no)
KR (1) KR950016743A (no)
CN (1) CN1109884A (no)
AU (1) AU8154394A (no)
CA (1) CA2138513A1 (no)
CZ (1) CZ322794A3 (no)
HU (1) HUT72314A (no)
IL (1) IL112047A0 (no)
NO (1) NO944926L (no)
NZ (1) NZ270184A (no)
PH (1) PH31556A (no)
RU (1) RU94044489A (no)
TW (1) TW272939B (no)
ZA (1) ZA9410096B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
JPH10513470A (ja) * 1995-02-06 1998-12-22 イーライ・リリー・アンド・カンパニー Ｉｌ−６の効果を阻害する方法
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5719190A (en) * 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
WO1999059561A2 (en) * 1998-05-18 1999-11-25 Hensley, Kenneth, L. Resveratrol inhibition of myeloperoxidase
CZ20013912A3 (cs) 1999-05-04 2002-05-15 Strakan Limited Androgen glykosid, sloučenina, testosteron-ß-D-glukosid, 5 alfa-Dihydrotestosteron- 17ß-D-glukosid, farmaceutický prostředek a pouľití sloučeniny
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20040167112A1 (en) * 2003-01-06 2004-08-26 Wyeth Use of estrogen receptor alpha modulators for the treatment of multiple sclerosis
DE602005020755D1 (de) * 2004-03-05 2010-06-02 Univ Illinois Peptidträger für die verabreichung von arzneimitteln
WO2007120097A1 (en) * 2006-04-13 2007-10-25 Astrazeneca Ab Thioxanthine derivatives and their use as inhibitors of mpo
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
NZ245260A (en) * 1991-11-27 1995-06-27 Novo Nordisk As Piperidine derivatives, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
PH31556A (en) 1998-11-03
HU9403677D0 (en) 1995-02-28
JPH07242546A (ja) 1995-09-19
HUT72314A (en) 1996-04-29
IL112047A0 (en) 1995-03-15
US5708009A (en) 1998-01-13
CN1109884A (zh) 1995-10-11
KR950016743A (ko) 1995-07-20
AU8154394A (en) 1995-06-29
RU94044489A (ru) 1996-10-20
NO944926D0 (no) 1994-12-19
CZ322794A3 (en) 1995-08-16
ZA9410096B (en) 1996-06-19
US5708010A (en) 1998-01-13
CA2138513A1 (en) 1995-06-22
EP0664125A1 (en) 1995-07-26
NZ270184A (en) 1999-07-29
TW272939B (no) 1996-03-21

Similar Documents

Publication Publication Date Title
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
NO944928L (no) Fremgangsmåter for inhibering av Alzheimers sykdom
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
WO1999033858A3 (en) Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
AU7578894A (en) Methods for inhibiting smooth muscle cell proliferation and restinosis
NO944934L (no) Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom
DK0652005T3 (da) Fremgangsmåder til inhibering af endometriose
NO944930L (no) Hemming av dysfunksjonell uterin blödning
NO951646D0 (no) Nye merkaptoacetylamid-bisykliske laktamderivater som er anvendbare som inhibitorer av enkefalinase og ACE
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
UA32427C2 (uk) Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO944924L (no) Fremgangsmåter for inhibering av Turner&#39;s syndrom
NO944931L (no) Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet
MY132085A (en) Methods for inhibiting bone prosthesis degeneration
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO960441L (no) Benzopyraner og farmasöytiske forbindelser inneholdende dem
TNSN93107A1 (fr) Derives de piperidine, leur preparation et leur application en therapeutique
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I